UPDATED:
Here is a link to the recording of the seminar. Please see Professor Outterson’s slideshow for more detail and explanation.
Original
On Tuesday, November 17, 2015, at 2:30pm Eastern Time (Washington, DC), KEI will host a seminar on antibiotic delinkage featuring Kevin Outterson, a Professor of Health Law, Bioethics & Human Rights at Boston University’s School of Law.
You can follow the presentation live here: http://youtu.be/4EhWaD6lQgs
The seminar will take place at the KEI office in Dupont Circle, and up to 10 persons can be participate remotely, via a video Google Hangout link. There is also an option to participate via telephone. If there is a capacity issue for the remote participation by video, we will give priority to academics, government officials, NGOs working on drug pricing, and third party payers.
After the seminar, the discussion will be posted online via YouTube and will be available to the public for research and reference purposes.
Professor Outterson will discuss antibiotic delinkage models, including ongoing work in DRIVE-AB by the European Union.
If you would like to participate, either through Google Hangouts or in person at our DC office, please fill out this Google Poll. Please contact Elizabeth Rajasingh via elizabeth.rajasingh[at]keionline.org with any additional questions. She will send out additional information regarding the seminar and instructions about joining the seminar on the morning of the event.
Kevin Outterson
Professor Kevin Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program and is the Pike Scholar in Health and Disability Law. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Professor Outterson was recently named to the Advisory Panel for the Longitude Prize, which awards £10 million to address antibiotic resistance.